Undiagnosed diabetes and impaired glucose metabolism on high-risk Spanish population. The IGT Study

BACKGROUND: To estimate the prevalence of undiagnosed diabetes and impaired glucose metabolism on high risk Spanish population, contrasting phenotypic features according to both sets of criteria, World Health Organization (WH O) and American Diabetes Association (ADA). SUBJECTS AND METHODS: Cross-sectional, multicentre (10 health-care centres, 230,000 inhabitants), selective risk-factor study. WHO diagnoses (normal, impaired glucose tolerance [IGT] and diabetes) were based on the 2 h plasma glucose (2hPG) following a 75 g oral glucose tolerance test (OGTT) and ADA diagnoses according the fasting plasma glucose (FPG) (normal, impaired FPG and diabetes). Prevalence, diagnostic overlap index and 22 clinical and bi ological parameters were compared. RESULTS: The study included 580 subjects (330 women), mean age 58.1 years a nd body mass index 31.2 kg/m(2), 292 (50,3%) with only one risk factor and 288 (49.7%) with two or more risk factors. WHO diagnoses were: 291 (50.2%) normal glucose tolerance (95% CI: 46.2-54.2%), 157 (27.1%) IGT (23.5-30.7%) and 132 (22.7%) diabetes (19.3-26.1%). ADA diagnoses were: 355 (61.2%) nor mal FPG (57.2-65.2%), 146 (25.2%) IFG (21.7-28.7%) and 79 (13.6%) diabetes (10.9-16.3%). The prevalence of diabetes decreased 9.1% (from -11.4 to -6.8 %). The diagnostic overlap was 33.5% for diabetes and 19.3% for impaired gl ucose homeostasis (IGT-FPG). Omitting the OGTT half the diabetic subjects w ith 2hPG greater than or equal to 200 mg/dl (11.1 mM) but FPG < 126 mg/dl ( 7mM) would remain undiagnosed. By changing screening criteria (FPG instead of 2hPG) the risk related to traditional factors such as age or a first-deg ree relative with diabetes would reduce. CONCLUSIONS: Applying ADA criteria, the high prevalence of undiagnosed gluc ose abnormalities would decrease. These results suggest that it is strongly advisable the continued use of the 2hPG for diabetes screenig on high risk Spanish population.